Skip to content

Study · Animal study (in vivo) · mouse · 2025

2 results

YTHDF1-mediated mitochondrial dysfunction and allergic airway inflammation by interaction with β-catenin/TCF4 signaling.

Xie C, Huang J, Chen Y, Huang B, Chen Y, Li Y, Gong Z, Ma Y, Xu M, Fan K, Hu D, Zhao X and 5 more

Show all authors

Huang P, Peng X, Cai S, Zhao W, Zhao H

International immunopharmacology8 Jul 2025Cited by 5 (Europe PMC)

PMID40633209 (opens in a new tab)DOI10.1016/j.intimp.2025.115181 (opens in a new tab)PepBankPUB-40633209
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TDI-induced asthma, SS‑31 triacetate significantly decreased airway inflammation.

    In plain wordsIn mice with asthma caused by TDI, SS‑31 triacetate lowered airway inflammation.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTDI-induced airway inflammation
    Study

    mousen: not reported in source

    TDI-induced asthma model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The TDI-induced airway inflammation, as well as mitochondrial dysfunction, were both significantly decreased after treatment with SS-31 triacetate.
    1 context sentence
    Summary · context
    Mice were administered the YHTDF1 m6A modification inhibitor (Tegaserod), the β-catenin/TCF4 signaling inhibitor (LF3), and the mitochondrial stabilizing drug SS-31 triacetate.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TDI-induced asthma, SS‑31 triacetate significantly decreased mitochondrial dysfunction.

    In plain wordsIn mice with asthma caused by TDI, SS‑31 triacetate reduced mitochondrial dysfunction.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTDI-induced mitochondrial dysfunction
    Study

    mousen: not reported in source

    TDI-induced asthma model
    Outcome group
    Mitochondrial function · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The TDI-induced airway inflammation, as well as mitochondrial dysfunction, were both significantly decreased after treatment with SS-31 triacetate.
    1 context sentence
    Summary · context
    Mice were administered the YHTDF1 m6A modification inhibitor (Tegaserod), the β-catenin/TCF4 signaling inhibitor (LF3), and the mitochondrial stabilizing drug SS-31 triacetate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.